{
    "clinical_study": {
        "@rank": "119525", 
        "arm_group": [
            {
                "arm_group_label": "Darifenacin + Physiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms."
            }, 
            {
                "arm_group_label": "Physiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill."
            }
        ], 
        "brief_summary": {
            "textblock": "Overactive bladder is a common problem among adult women. Darifenacin is an antimuscarinic\n      drug that is frequently used as part of the management of the condition. However, current\n      evidence backing its use is limited. This study aims to address Darifenacin's effectiveness\n      in adjunct to physiotherapy in treating symptoms due to overactive bladder."
        }, 
        "brief_title": "Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with overactive bladder as diagnosed and confirmed by a urologist.\n\n          -  Able to answer the ICIC, King's Health Questionnaire and Overactive Bladder\n             Questionnaire.\n\n          -  Able and willing to receive urodynamic studies.\n\n        Exclusion Criteria:\n\n          -  History of pelvic radiotherapy.\n\n          -  Recent pelvic surgery (<1 year).\n\n          -  History of anti-incontinence surgery.\n\n          -  Pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143570", 
            "org_study_id": "635"
        }, 
        "intervention": [
            {
                "arm_group_label": "Darifenacin + Physiotherapy", 
                "description": "Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.", 
                "intervention_name": "Darifenacin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Oralafi", 
                    "Darisec", 
                    "Continex", 
                    "Emselex", 
                    "Enablex"
                ]
            }, 
            {
                "arm_group_label": [
                    "Darifenacin + Physiotherapy", 
                    "Physiotherapy"
                ], 
                "description": "All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.", 
                "intervention_name": "Physiotherapy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darifenacin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Urinary Bladder, Overactive", 
            "Darifenacin", 
            "Physiotherapy", 
            "Quality of Life"
        ], 
        "lastchanged_date": "May 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valparaiso", 
                    "country": "Chile", 
                    "zip": "2341131"
                }, 
                "name": "Hospital Carlos Van Buren"
            }
        }, 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women", 
        "overall_official": {
            "affiliation": "Senior Urologist", 
            "last_name": "Melissa Cifuentes, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Chile: Comit\u00e9 de \u00c9tica Cient\u00edfico", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall quality of life as established by the Overactive Bladder Questionnaire.", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143570"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidad de Valparaiso", 
            "investigator_full_name": "Felipe Martinez", 
            "investigator_title": "M.D., M.Sc.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Presence of symptoms of overactive bladder, as established by the King's Health Questionnaire and the International Consultation on Incontinence Questionnaire.", 
                "measure": "Overactive Bladder Symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Development of any adverse event attributable to darifenacin and as established by a standardised questionnaire.", 
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Universidad de Valparaiso", 
        "sponsors": {
            "collaborator": {
                "agency": "Recalcine (GynoPharm)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Universidad de Valparaiso", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}